Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma
- PMID:18054825
- DOI: 10.1016/j.eururo.2007.11.037
Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma
Abstract
Objective: To provide a systematic review of the side effects associated with sorafenib, sunitinib, and temsirolimus and to provide an outline of possible preventive or therapeutic measures.
Methods: We performed a PubMed-based systematic review of side effects associated with the three agents and relied on product monographs and prescribing information to provide an outline of treatments aimed at reducing these toxicities.
Results: Side effects range from <1% to 72%. Grade 3/4 side effects are less common and range from <1% to 13% for sorafenib, <1% to 16% for sunitinib, and 1% to 20% for temsirolimus. Overall, sunitinib causes the most grade 3/4 side effects and sorafenib causes the fewest grade 3/4 side effects, although head-to-head trials are required to compare safety profiles of all three kinase inhibitors. Virtually all side effects can be managed effectively.
Conclusion: Prevention, recognition, and prompt management of side effects are of key importance and avoid unnecessary dose reductions, which may undermine treatment efficacy.
Similar articles
- Management of sorafenib, sunitinib, and temsirolimus toxicity in metastatic renal cell carcinoma.Guevremont C, Alasker A, Karakiewicz PI.Guevremont C, et al.Curr Opin Support Palliat Care. 2009 Sep;3(3):170-9. doi: 10.1097/SPC.0b013e32832e4681.Curr Opin Support Palliat Care. 2009.PMID:19528803Review.
- Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies.Hutson TE, Figlin RA, Kuhn JG, Motzer RJ.Hutson TE, et al.Oncologist. 2008 Oct;13(10):1084-96. doi: 10.1634/theoncologist.2008-0120. Epub 2008 Oct 6.Oncologist. 2008.PMID:18838439Review.
- Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation.Thompson Coon J, Hoyle M, Green C, Liu Z, Welch K, Moxham T, Stein K.Thompson Coon J, et al.Health Technol Assess. 2010 Jan;14(2):1-184, iii-iv. doi: 10.3310/hta14020.Health Technol Assess. 2010.PMID:20028613Review.
- Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.La Vine DB, Coleman TA, Davis CH, Carbonell CE, Davis WB.La Vine DB, et al.Am J Clin Oncol. 2010 Jun;33(3):217-20. doi: 10.1097/COC.0b013e3181a650a6.Am J Clin Oncol. 2010.PMID:19745694
- Update on systemic therapies of metastatic renal cell carcinoma.Herrmann E, Bierer S, Wülfing C.Herrmann E, et al.World J Urol. 2010 Jun;28(3):303-9. doi: 10.1007/s00345-010-0519-5. Epub 2010 Feb 24.World J Urol. 2010.PMID:20180125Review.
Cited by
- Combination of a proteomics approach and reengineering of meso scale network models for prediction of mode-of-action for tyrosine kinase inhibitors.Balabanov S, Wilhelm T, Venz S, Keller G, Scharf C, Pospisil H, Braig M, Barett C, Bokemeyer C, Walther R, Brümmendorf TH, Schuppert A.Balabanov S, et al.PLoS One. 2013;8(1):e53668. doi: 10.1371/journal.pone.0053668. Epub 2013 Jan 9.PLoS One. 2013.PMID:23326482Free PMC article.
- Current status of targeted therapy for advanced renal cell carcinoma.Cho IC, Chung J.Cho IC, et al.Korean J Urol. 2012 Apr;53(4):217-28. doi: 10.4111/kju.2012.53.4.217. Epub 2012 Apr 18.Korean J Urol. 2012.PMID:22536463Free PMC article.
- The Underestimated Role of the p53 Pathway in Renal Cancer.Amendolare A, Marzano F, Petruzzella V, Vacca RA, Guerrini L, Pesole G, Sbisà E, Tullo A.Amendolare A, et al.Cancers (Basel). 2022 Nov 22;14(23):5733. doi: 10.3390/cancers14235733.Cancers (Basel). 2022.PMID:36497215Free PMC article.Review.
- Onset of male gynaecomastia in a patient treated with sunitinib for metastatic renal cell carcinoma.Ballardini P, Margutti G, Aliberti C, Manfredini R.Ballardini P, et al.Clin Drug Investig. 2009;29(7):487-490. doi: 10.2165/00044011-200929070-00007.Clin Drug Investig. 2009.PMID:19499966
- Symptoms from treatment with sunitinib or sorafenib: a multicenter explorative cohort study to explore the influence of patient-reported outcomes on therapy decisions.Koldenhof JJ, Witteveen PO, de Vos R, Walraven M, Tillier CN, Verheul HM, Teunissen SC.Koldenhof JJ, et al.Support Care Cancer. 2014 Sep;22(9):2371-80. doi: 10.1007/s00520-014-2223-2. Epub 2014 Apr 2.Support Care Cancer. 2014.PMID:24687539
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical